JAMA study shows pharma companies struggle to meet postapproval study deadlines
When new drugs win approval in the US, the FDA often tasks sponsors with conducting postmarket studies as a condition of the OKs, with deadlines …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
